Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
rHu G-CSF More
The University of Edinburgh has perfected a genetic engineering strategy in mouse embryonic stem cells to replace large regions of mouse chromosomal sequences (>100kb) with the corresponding human syntenic region. More
A suite of highly specific, proprietary bacterial drug targets in staphylococcus aureus, that can be used individually or as a group to develop small molecule or peptide drug leads with powerful anti-infectives properties. More
POL6326, a CXCR4 antagonist, currently in Phase I clinical studies More
Use of depth filters to remove prion infectivity from plasma - derived therapeutic products and/or other biologics. Depth Filtration is a chemically inactive process and therefore does not introduce potentially toxic bi-products or alter components. More
Naturally occurring compound shown to inhibit and reverse fatty liver. More
Proprietary manufacturing process for a liquid IVIgG product - in great demand world-wide as one of the principal therapeutics obtained from blood plasma. Process delivers a low IgA content, which increases renal tolerability. More
Proprietary process to produce a freeze-dried fibrinogen therapeutic product, easily soluble. Includes two virus inactivation processes: dry heat treatment and solvent/detergent. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Blood composition
- Blood disorders
- Blood substitute
- Blood Transfusion
- Fibrogenesis
- Hemorrhagic trauma
- Lymphatic disorders
- Sepsis
- Thrombosis
- Whole blood substitute
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us